Prevalence, Diagnosis and Management of Immune Thrombocytopenic Purpura (ITP) in Saudi Arabia

Abstract

This comprehensive review explores the prevalence, diagnostic approaches, and management strategies for ITP in Saudi Arabia, highlighting the ongoing challenges and future directions for research and clinical practice in this field. Immune Thrombocytopenic Purpura (ITP) is a hematological disorder characterized by a significant reduction in platelet count due to the immune system's inappropriate response against platelets. This condition can lead to various clinical manifestations, including easy bruising, mucosal bleeding, and, in severe cases, life-threatening hemorrhages. The pathophysiology of ITP involves the production of autoantibodies that target platelet antigens, resulting in increased platelet destruction primarily in the spleen and other reticuloendothelial tissues. In Saudi Arabia, the prevalence of ITP has become a significant public health concern, influenced by unique demographic, genetic, and environmental factors. Epidemiological studies indicate that ITP can present in both primary and secondary forms, with secondary ITP often associated with underlying conditions such as infections, autoimmune diseases, or malignancies. The demographic characteristics of patients with ITP in Saudi Arabia reveal a slight female predominance, particularly in the adult population, and variations in age of onset between pediatric and adult cases. The diagnosis of ITP is primarily clinical, supported by laboratory investigations, including complete blood counts and specific assays to exclude other causes of thrombocytopenia. The management of ITP in Saudi Arabia is multifaceted, encompassing both medical and surgical interventions. First-line treatments typically include corticosteroids and intravenous immunoglobulin (IVIG), while splenectomy may be considered for patients who do not respond to medical therapy. Emerging therapies, such as thrombopoietin receptor agonists, are also being explored as potential treatment options. Despite advancements in the understanding and management of ITP, challenges remain, including variations in healthcare access, differences in clinical practice guidelines, and the need for increased awareness among healthcare professionals.